GlassScriptPhysician profile
Judith Haggard
NPI 1619088390
$1,253.75
in general payments reported to CMS, 2019-2025
15 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $80.74 · 2023: $422 · 2024: $295 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $405.28 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $329.95 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.71 | 2021-2024 | Tradjenta, Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $88.08 | 2023 | |
| Amgen INC. | $59.01 | 2021-2024 | Otezla, Repatha |
| Sumitomo Pharma America, INC. | $49.82 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $35.26 | 2021 | |
| Glaxosmithkline, LLC. | $27.90 | 2021-2023 | Shingrix |
| Merck Sharp & Dohme LLC | $26.86 | 2021-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Viatris Specialty LLC | $18.92 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $18.33 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.05 | 2025 | Breztri |
| Grifols USA, LLC | $14.01 | 2024 | Prolastin-C Liquid |
| Organon LLC | $12.87 | 2023 | Nexplanon |
| Roche Diagnostics Corporation | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Haggard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.